Ossdsign Catalyst News Today

"OssDsign secures contract with U.S. Department of Veterans Affairs to provide orthobiologic products to 100 additional VA hospitals nationwide, expanding acces

STOCKHOLM – 26 April 2024. Karolinska Development AB today publishes its Interim Report - January-March 2024. The full report is available on the Companys website. “2024 has begun strongly with...

STOCKHOLM – 16 February 2024. Karolinska Development AB today publishes its Year-end Report - January-December 2023. The full report is available on the Companys website. “2023 has been a year...

Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst.

Uppsala, January 9, 2024. OssDsign AB today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 %...

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%...

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst. The data, that has been submitted to a peer-reviewed scientific journal, indicates that the use of OssDsign Catalyst lead

STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary...

STOCKHOLM – 17 November 2023. Karolinska Development AB today publishes its Interim Report - January-September 2023. The full report is available on the Companys website. “It’s clear that our...

Ossdsign AB will abandon its 3D-printed cranial reconstructive implant business to focus on U.S. sales of its Ossdsign Catalyst, an off-the-shelf nanosynthetic bone graft that offers gross margins of 90% or better. The new strategy sharply reduces the capital required before the company projects achieving a cash-flow positive position.